Kuman Tunçel Özlem, Akdeniz Fisun, Özbek Süha Süreyya, Kavukçu Gülgün, Ünal Kocabaş Gökçen
Department of Psychiatry, İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey.
Psychiatrist, Private Practice, İzmir, Turkey.
Noro Psikiyatr Ars. 2017 Jun;54(2):108-115. doi: 10.5152/npa.2017.12457. Epub 2017 Jun 1.
Lithium has many effects on thyroid physiology. Although these side effects have been known for a long time, large sample studies of lithium-treated patients using ultrasonography are lacking. The aim of this study is to investigate the detailed thyroid morphologies, hormone levels, and antibodies of lithium-treated patients compared with healthy controls.
This cross-sectional study involved 84 lithium-treated patients with bipolar disorder and 65 gender and age similar controls who had never been exposed to lithium. Subjects between 18 and 65 years of age were eligible for the study. Venous blood samples were acquired to determine the levels of free thyroxine (fT4), thyroid stimulating hormone (TSH), and thyroid antibodies; also, ultrasonographic examinations of the patients' thyroid glands were performed.
There were no statistically significant differences in smoking habits, known thyroid disease, thyroid medication use, familial thyroid disease, fT4 level, autoimmunity, thyroid nodule presence, or Hashimoto's thyroiditis between the lithium and control groups. The median TSH level and thyroid volume were significantly higher in the lithium group. In the lithium group, 14 cases (16.7%) of hypothyroidism, seven cases (8.3%) of subclinical hypothyroidism, and one case (1.2%) of subclinical hyperthyroidism were defined; in the control group, seven cases (10.8%) of hypothyroidism and two cases (3.1%) of subclinical hyperthyroidism were defined. Thyroid dysfunction, goiter, parenchymal abnormality, ultrasonographically defined thyroid abnormality, and thyroid disorder were found to be more prevalent in the lithium group. 90% of patients with goiter and 74.3% of patients with ultrasonographic pathologies were euthyroid.
It is important to note that 90% of the patients with goiter were euthyroid. This indicates that monitoring by blood test alone is insufficient. The prevalence rates of 47.6% for goiter and 83.3% for ultrasonographic pathology demonstrate that ultasonographic follow-up may be useful in lithium-treated patients. To determine whether routine ultrasonographic examination is necessary, large sample prospective studies are necessary due to the limitations of this study.
锂对甲状腺生理有多种影响。尽管这些副作用早已为人所知,但缺乏对使用锂治疗的患者进行超声检查的大样本研究。本研究的目的是调查与健康对照相比,使用锂治疗的患者的详细甲状腺形态、激素水平和抗体情况。
这项横断面研究纳入了84例患有双相情感障碍且接受锂治疗的患者以及65例性别和年龄相仿且从未接触过锂的对照者。年龄在18至65岁之间的受试者符合研究条件。采集静脉血样本以测定游离甲状腺素(fT4)、促甲状腺激素(TSH)和甲状腺抗体水平;同时,对患者的甲状腺进行超声检查。
锂治疗组和对照组在吸烟习惯、已知甲状腺疾病、甲状腺药物使用、家族性甲状腺疾病、fT4水平、自身免疫、甲状腺结节存在情况或桥本甲状腺炎方面无统计学显著差异。锂治疗组的TSH中位数水平和甲状腺体积显著更高。在锂治疗组中,定义了14例(16.7%)甲状腺功能减退、7例(8.3%)亚临床甲状腺功能减退和1例(1.2%)亚临床甲状腺功能亢进;在对照组中,定义了7例(10.8%)甲状腺功能减退和2例(3.1%)亚临床甲状腺功能亢进。甲状腺功能障碍、甲状腺肿、实质异常、超声定义的甲状腺异常和甲状腺疾病在锂治疗组中更为普遍。90%的甲状腺肿患者和74.3%的有超声检查病变的患者甲状腺功能正常。
需要注意的是,90%的甲状腺肿患者甲状腺功能正常。这表明仅通过血液检测进行监测是不够的。甲状腺肿患病率为47.6%,超声检查病变患病率为83.3%,这表明超声随访可能对接受锂治疗的患者有用。由于本研究的局限性,有必要进行大样本前瞻性研究以确定是否有必要进行常规超声检查。